本文選題：天麥消渴片 + 型糖尿病　； 參考：《中藥新藥與臨床藥理》2017年06期

【摘要】：目的系統(tǒng)評價天麥消渴片對2型糖尿病患者胰島功能指標的影響。方法計算機檢索中文全文期刊數據庫(CNKI),萬方數據庫(Wan Fang Data),中國生物醫(yī)學文獻數據庫(Sino Med),維普數據庫(VIP)、Pub Med、The Cochrane Library以及Embase數據庫,納入有關天麥消渴片對2型糖尿病患者胰島功能影響的隨機對照試驗(RCT),檢索時限均為建庫至2017年9月,由2位研究者獨立進行文獻篩選、資料提取及納入研究的質量評價,意見不一致時討論解決。結果納入23個隨機對照試驗(RCT),結局指標包括胰島素抵抗指數(HOMA-IR)、胰島β細胞基礎分泌指數(HOMA-β)、空腹血漿葡萄糖(FPG)、餐后2 h血糖(2h PPG)以及不良反應。結果顯示,在降低HOMA-IR指標方面,天麥消渴片降低胰島素抵抗指數作用優(yōu)于安慰劑(SMD=1.61,95%CI[1.20,2.03])P0.00001、噻唑烷二酮類(SMD=0.28,95%CI[0.03,0.53])P=0.03、雙胍類(SMD=1.43,95%CI[0.90,1.96])P0.00001、門冬胰島素(SMD=1.17,95%CI[0.75,1.59])P0.00001。此外,與噻唑烷二酮類(SMD=0.53,95%CI[0.07,0.98])P=0.02、糖苷酶抑制劑(SMD=1.05,95%CI[0.58,1.52])P0.00001、雙胍類(SMD=0.49,95%CI[0.28,0.71])P0.00001、磺脲類(SMD=8.57,95%CI[7.27,9.88])P0.00001聯(lián)用均顯示出增效作用;在升高HOMA-β指標方面,天麥消渴片與雙胍類(SMD=0.75,95%CI[0.25,1.25])P=0.004、噻唑烷二酮類(SMD=0.59,95%CI[0.01,1.18])P=0.05、磺脲類(SMD=1.53,95%CI[1.08,1.99])P0.00001以及門冬胰島素(SMD=0.59,95%CI[0.16,1.02])P=0.008聯(lián)用均顯示出增效作用;在降低FPG指標方面,天麥消渴片療效優(yōu)于安慰劑(SMD=2.55,95%CI[2.06,3.03])P0.00001,其次,分別與噻唑烷二酮(SMD=1.06,95%CI[0.34,1.79])P=0.004、糖苷酶抑制劑(SMD=0.78,95%CI[0.33,1.24])P=0.0008以及雙胍類(SMD=0.56,95%CI[0.43,0.70])P0.00001聯(lián)用療效更好;在降低2h PPG指標方面,天麥消渴片療效優(yōu)于安慰劑(SMD=1.45,95%CI[1.05,1.85])P0.00001以及門冬胰島素(SMD=1.43,95%CI[1.00,1.86])P0.00001,其次與噻唑烷二酮(SMD=0.91,9 5%CI[0.47,1.36])P0.0001及雙胍類(SMD=0.51,95%CI[0.38,0.64])P0.00001聯(lián)用療效更好。此外,天麥消渴片與降糖藥物對比安全性較好。結論當前證據表明,天麥消渴片能降低HOMA-IR、FPG以及2h PPG,與部分陽性藥物聯(lián)用可增加療效,且安全性較好。由于納入研究普遍存在方法學質量問題,需要開展高質量的研究予以驗證。
[Abstract]:Objective to evaluate the effect of Tianmaixiaoke tablets on islet function in type 2 diabetic patients. Methods Chinese full-text periodical database (CNKI), Wan Fang data, Chinese biomedical literature database (Sino Med), VIP database (VIP), Pub Medbin the Cochrane Library and Embase database were searched by computer. A randomized controlled trial (RCT) was conducted on the effects of Tianmaixiaoke tablets on pancreatic islet function in type 2 diabetic patients. The retrieval time was from the establishment of the database to September 2017. The two researchers independently selected the literature, extracted the data and evaluated the quality of the study. Discuss a solution when there is disagreement. Results in 23 randomized controlled trials (RCT), the outcome indexes included insulin resistance index (HOMA-IR), basal secretion index of islet 尾 cells (HOMA- 尾), fasting plasma glucose (FPG), 2 h postprandial blood glucose (2 h PPG) and adverse reactions. The results showed that Tianmaixiaoke tablet had a better effect on reducing insulin resistance index than placebo (SMD-1.61N95 CI [1.20 鹵2.03]) P0.00001, thiazolidone diketone (SMD-0.28995 CI [0.030.53]) P0.03, biguanidine (SMD1.4395CI [0.901.96]) P0.00001, aspartate insulin (SMD1.17995 CI [0.750.59]) P0.00001. the index of insulin resistance in Tianmaixiaoke tablet was better than that in placebo (SMD-1.61N95 CI [1.20 鹵2.03]), thiazolidanedione diketone (SMD-0.2895 CI [0.030.53]), biguanidine (SMD-1.4395CI [0.90 鹵1.96]). In addition, in combination with thiazolidinediketone (SMD-0.53-95CI [0.070.98]) P0.02, glucosidase inhibitor (SMD-1.0595CI [0.581.52]) P0.00001, biguanidine (SMD-0.49c95 CI [0.280.71]) P0.00001, sulfonylurea (SMD-8.57 / 95CI [7.279.88]) showed synergistic effects; in raising HOMA- 尾, 澶╅害娑堟復鐗囦笌鍙岃儘綾，

本文編號：2065057